Natural Killer Cells

[Ebiomedicine] Lymphocytes and tissue sections of lymph node were collected from 11 HIV-1 positive antiretroviral therapy (ART)-naive and 19 HIV-1 negative donors.

[Acta Biomaterialia] Scientists assessed the local and systemic innate immune responses to implantation of biphasic calcium phosphate biomaterial alone, or with bone marrow derived MSC, in critical-sized calvarial bone defects of Lewis rats.

[Celularity, Inc.] Celularity, Inc. announced the FDA has granted Fast Track Designation for its non-genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer cell therapy, CYNK-001, in development for the treatment of acute myeloid leukemia (AML).

[International Journal of Biological Sciences] Efforts have been made to generate immune-escaping human embryonic stem cells where T cell immunity was evaded by defecting β-2-microglobulin, a common unit for human leukocyte antigen class I, and NK cells were inhibited via ectopic expression of HLA-E or -G.

[ImmunityBio, Inc.] ImmunityBio, Inc. has been granted a US patent for a novel natural killer cell therapy composition and method for treating cancer that combines the company’s genetically modified NK-92 cells with CD16 receptors to enhance binding and activity of monoclonal antibodies.

[Archives of Pharmacal Research] Investigators showed that several NSCLC cell lines have differential sensitivity to NK cell–mediated cytotoxicity: NCI-H522 cells were highly sensitive, but A549, NCI-H23, NCI-H1915, and NCI-H1299 were resistant.